The cost-effectiveness of navelbine alone or in combination with cisplatin in comparison to other chemotherapy regimens and best supportive care in stage IV non-small cell lung cancer
- 1 December 1996
- journal article
- research article
- Published by Elsevier in European Journal Of Cancer
- Vol. 32 (13) , 2249-2255
- https://doi.org/10.1016/s0959-8049(96)00298-5
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Diagnostic and therapeutic approaches to lung cancer in Canada and their costsBritish Journal of Cancer, 1995
- Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trialsBMJ, 1995
- Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients.Journal of Clinical Oncology, 1994
- Chemotherapy for advanced non-small-cell lung cancer: how much benefit is enough?Journal of Clinical Oncology, 1993
- Polychemotherapy in advanced non small cell lung cancer: a meta-analysisThe Lancet, 1993
- Counting the costs of chemotherapy in a National Cancer Institute of Canada randomized trial in nonsmall-cell lung cancer.Journal of Clinical Oncology, 1990
- Quality of Life During Chemotherapy in Non-Small Cell Lung Cancer PatientsActa Oncologica, 1989
- Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer--report of a Canadian multicenter randomized trial.Journal of Clinical Oncology, 1988
- A randomized trial of the four most active regimens for metastatic non-small-cell lung cancer.Journal of Clinical Oncology, 1986
- Combination chemotherapy with bleomycin, etoposide, and cisplatin in metastatic non-small-cell lung cancer.Journal of Clinical Oncology, 1985